Moray G, Karakayali F, Yilmaz U, Ozcay F, Bilezikci B, Haberal M
Department of General Surgery, Başkent University Faculty of Medicine, Ankara, Turkey.
Transplant Proc. 2007 May;39(4):1171-4. doi: 10.1016/j.transproceed.2007.02.056.
In this study, we evaluated our early results of liver transplantation for hepatocellular carcinoma (HCC). Between January 2004 and June 2006, 26 patients (4 females, 22 males; aged 1.1-65 years) with preoperatively diagnosed or incidental HCC underwent liver transplantation at our center. Inclusion criteria (independent of tumor size and number of tumor nodules) were no invasion of major vascular structures and no evidence of extrahepatic disease. In 13 of the patients, tumors were beyond the Milan criteria. At this writing, at a mean follow-up of 16.5 months (range, 1-31 months), all patients were doing well with excellent graft function. The longest survival is 2.5 years, and our patient survival rate is 100%. There has been only 1 tumor recurrence, which occurred 4 months after liver transplantation. In conclusion, liver transplantation provides long patient and disease-free survival, even in patients with HCC that exceeds the Milan criteria.
在本研究中，我们评估了肝细胞癌（HCC）肝移植的早期结果。2004年1月至2006年6月期间，26例术前诊断或偶然发现HCC的患者（4例女性，22例男性；年龄1.1 - 65岁）在我们中心接受了肝移植。纳入标准（与肿瘤大小和肿瘤结节数量无关）为主要血管结构未受侵犯且无肝外疾病证据。13例患者的肿瘤超出了米兰标准。撰写本文时，平均随访16.5个月（范围1 - 31个月），所有患者情况良好，移植肝功能极佳。最长生存期为2.5年，患者生存率为100%。仅发生1例肿瘤复发，于肝移植后4个月出现。总之，即使对于超出米兰标准的HCC患者，肝移植也能实现患者长期生存且无疾病复发。
